Contact activation by the intrinsic pathway of blood plasma coagulation

Y. Yan, L. C. Xu, E. A. Vogler, C. A. Siedlecki

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

It is well known that the biomaterial surfaces that comprise biomedical devices will initiate blood coagulation. This can occur through the adhesion and activation of platelets, but also through the activation of the proteins of the intrinsic coagulation cascade. Nominally, this involves activation of the zymogen FXII (Hageman Factor) which in turn activates FXI, prekallikrein and high-molecular-weight kininogen to form an activation complex. The end result of this sequence of zymogen/enzyme conversion steps is the production of thrombin, the conversion of fibrinogen to fibrin and the development of fibrin strands. In this chapter, we discuss the proteins of the intrinsic pathway, the traditional view of contact activation, and finally alternative ideas about the activation of this important pathway. Notably, we attempt to reconcile the inconsistencies between protein adsorption and function at biomaterial surfaces and the traditional views of contact activation.

Original languageEnglish (US)
Title of host publicationHemocompatibility of Biomaterials for Clinical Applications
Subtitle of host publicationBlood-Biomaterials Interactions
PublisherElsevier Inc.
Pages3-28
Number of pages26
ISBN (Electronic)9780081004999
ISBN (Print)9780081004975
DOIs
StatePublished - Jan 1 2018

Fingerprint

Blood Coagulation
Enzyme Precursors
Biocompatible Materials
Fibrin
High Molecular Weight Kininogens
Prekallikrein
Factor XII
Proteins
Platelet Activation
Thrombin
Fibrinogen
Adsorption
Equipment and Supplies
Enzymes

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Health Professions(all)

Cite this

Yan, Y., Xu, L. C., Vogler, E. A., & Siedlecki, C. A. (2018). Contact activation by the intrinsic pathway of blood plasma coagulation. In Hemocompatibility of Biomaterials for Clinical Applications: Blood-Biomaterials Interactions (pp. 3-28). Elsevier Inc.. https://doi.org/10.1016/B978-0-08-100497-5.00001-X
Yan, Y. ; Xu, L. C. ; Vogler, E. A. ; Siedlecki, C. A. / Contact activation by the intrinsic pathway of blood plasma coagulation. Hemocompatibility of Biomaterials for Clinical Applications: Blood-Biomaterials Interactions. Elsevier Inc., 2018. pp. 3-28
@inbook{8d81ae996a6a4c8783a5d935f75a6def,
title = "Contact activation by the intrinsic pathway of blood plasma coagulation",
abstract = "It is well known that the biomaterial surfaces that comprise biomedical devices will initiate blood coagulation. This can occur through the adhesion and activation of platelets, but also through the activation of the proteins of the intrinsic coagulation cascade. Nominally, this involves activation of the zymogen FXII (Hageman Factor) which in turn activates FXI, prekallikrein and high-molecular-weight kininogen to form an activation complex. The end result of this sequence of zymogen/enzyme conversion steps is the production of thrombin, the conversion of fibrinogen to fibrin and the development of fibrin strands. In this chapter, we discuss the proteins of the intrinsic pathway, the traditional view of contact activation, and finally alternative ideas about the activation of this important pathway. Notably, we attempt to reconcile the inconsistencies between protein adsorption and function at biomaterial surfaces and the traditional views of contact activation.",
author = "Y. Yan and Xu, {L. C.} and Vogler, {E. A.} and Siedlecki, {C. A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/B978-0-08-100497-5.00001-X",
language = "English (US)",
isbn = "9780081004975",
pages = "3--28",
booktitle = "Hemocompatibility of Biomaterials for Clinical Applications",
publisher = "Elsevier Inc.",
address = "United States",

}

Yan, Y, Xu, LC, Vogler, EA & Siedlecki, CA 2018, Contact activation by the intrinsic pathway of blood plasma coagulation. in Hemocompatibility of Biomaterials for Clinical Applications: Blood-Biomaterials Interactions. Elsevier Inc., pp. 3-28. https://doi.org/10.1016/B978-0-08-100497-5.00001-X

Contact activation by the intrinsic pathway of blood plasma coagulation. / Yan, Y.; Xu, L. C.; Vogler, E. A.; Siedlecki, C. A.

Hemocompatibility of Biomaterials for Clinical Applications: Blood-Biomaterials Interactions. Elsevier Inc., 2018. p. 3-28.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Contact activation by the intrinsic pathway of blood plasma coagulation

AU - Yan, Y.

AU - Xu, L. C.

AU - Vogler, E. A.

AU - Siedlecki, C. A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - It is well known that the biomaterial surfaces that comprise biomedical devices will initiate blood coagulation. This can occur through the adhesion and activation of platelets, but also through the activation of the proteins of the intrinsic coagulation cascade. Nominally, this involves activation of the zymogen FXII (Hageman Factor) which in turn activates FXI, prekallikrein and high-molecular-weight kininogen to form an activation complex. The end result of this sequence of zymogen/enzyme conversion steps is the production of thrombin, the conversion of fibrinogen to fibrin and the development of fibrin strands. In this chapter, we discuss the proteins of the intrinsic pathway, the traditional view of contact activation, and finally alternative ideas about the activation of this important pathway. Notably, we attempt to reconcile the inconsistencies between protein adsorption and function at biomaterial surfaces and the traditional views of contact activation.

AB - It is well known that the biomaterial surfaces that comprise biomedical devices will initiate blood coagulation. This can occur through the adhesion and activation of platelets, but also through the activation of the proteins of the intrinsic coagulation cascade. Nominally, this involves activation of the zymogen FXII (Hageman Factor) which in turn activates FXI, prekallikrein and high-molecular-weight kininogen to form an activation complex. The end result of this sequence of zymogen/enzyme conversion steps is the production of thrombin, the conversion of fibrinogen to fibrin and the development of fibrin strands. In this chapter, we discuss the proteins of the intrinsic pathway, the traditional view of contact activation, and finally alternative ideas about the activation of this important pathway. Notably, we attempt to reconcile the inconsistencies between protein adsorption and function at biomaterial surfaces and the traditional views of contact activation.

UR - http://www.scopus.com/inward/record.url?scp=85041240080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041240080&partnerID=8YFLogxK

U2 - 10.1016/B978-0-08-100497-5.00001-X

DO - 10.1016/B978-0-08-100497-5.00001-X

M3 - Chapter

AN - SCOPUS:85041240080

SN - 9780081004975

SP - 3

EP - 28

BT - Hemocompatibility of Biomaterials for Clinical Applications

PB - Elsevier Inc.

ER -

Yan Y, Xu LC, Vogler EA, Siedlecki CA. Contact activation by the intrinsic pathway of blood plasma coagulation. In Hemocompatibility of Biomaterials for Clinical Applications: Blood-Biomaterials Interactions. Elsevier Inc. 2018. p. 3-28 https://doi.org/10.1016/B978-0-08-100497-5.00001-X